Organisation paid for research Program year 2025 Source: CMS Open Payments

Clincloud LLC

Neither a doctor nor a teaching hospital

Research payments

$8,853,624

586 payments

Through program year 2025, Clincloud LLC is reported as receiving $8,853,624 in research payments, across 586 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$672,140	38
2024	Research	$2,168,349	151
2023	Research	$826,643	85
2022	Research	$874,202	90
2021	Research	$2,448,132	130
2020	Research	$1,435,916	66
2019	Research	$428,242	26

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $3,006,140 171 payments
Regeneron Pharmaceuticals, Inc. $2,008,582 86 payments
AbbVie, Inc. $1,688,494 61 payments
Braintree Laboratories, Inc. $684,992 59 payments
Vanda Pharmaceuticals Inc. $653,323 92 payments
Janssen Research & Development, LLC $490,673 83 payments
E.R. Squibb & Sons, L.L.C. $171,128 9 payments
Novartis Pharmaceuticals Corporation $95,663 13 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $26,659 1 payment
Allergan Inc. $19,671 7 payments

Studies the money was for Research payments · program years 2019–2025

Gantenerumab in Early Ad $1,548,768 82 payments
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $1,511,753 44 payments
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease $1,192,547 36 payments
Q1w Dosing $816,627 37 payments
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease $624,320 45 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis $436,400 51 payments
Postgraduate Roll Over Study $350,687 38 payments
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease $297,909 36 payments
A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $280,468 21 payments
Prevention Study $247,642 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.